MedTrace Logo

Surveillance of Vaccine-induced Immunity Against Ebola in Previously Vaccinated Health Care Workers

NCT05313139 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 133

Last updated 2026-03-19

No results posted yet for this study

Summary

During the previous Ebola virus disease (EVD) outbreaks, the institute National de Recherche Biomédicale (INRB) and other institutional's staff in Democratic Republic of the Congo (DRC) got vaccinated with the rVSV-ZEBOV vaccine. However, the longevity of Ebola virus (EBOV)-specific immune responses after vaccination has not been studied extensively (only 1-2 years) nor comprehensively (only humoral), despite the wide use of this vaccine. With the re-emergence of Ebola in North-Kivu from a previously vaccinated individual, and the new planned vaccination campaign (considering homologous booster doses for previously vaccinated HCW) in light of the new outbreak in Beni, assessing the persistence and quality of vaccine-induced anti-EBOV immune responses is pertinent and timely.

Conditions

  • Immune Response

Sponsors & Collaborators

  • Institute of Tropical Medicine, Belgium

    lead OTHER

Principal Investigators

  • Mulangu Sabue, Prof · Institut National de Recherche Biomédicale (INRB), Kinshasa

  • Kavunga Hugo, Prof · Institut National de Recherche Biomédicale (INRB), Goma

  • Mukadi Daniel, MD · Institut National de Recherche Biomédicale (INRB), Goma

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-13
Primary Completion
2022-02-01
Completion
2025-03-03

Countries

  • Democratic Republic of the Congo

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05313139 on ClinicalTrials.gov